Clinical Trial

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

Study acronym: LINC CARE
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically significant reductions in blood pressure and glycaemia. This study aims at providing additional evidence on the safety, efficacy and appropriate dosing of osilodrostat in patients with CS, who have hypertension.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07247162
Lead Sponsor RECORDATI GROUP
Conditions Hypertension, Hypercortisolemia, Cushing Syndrome
Enrollment 63 participants
Start Date 2026-08
Primary Completion 2028-05 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-12-10